Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

NCT04678102 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer
Platinum-refractory Ovarian Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma

Interventions

DRUG: PHI-101 administration

Sponsor

Seoul National University Hospital

Collaborators

[object Object]